BCG Vaccines Market Size

BCG Vaccines Market Size

BCG Vaccines Market size was valued at USD 88.3 million in 2023 and is anticipated to witness growth at a CAGR of 5.4% between 2024 and 2032. BCG vaccines are live attenuated vaccines derived from a strain of Mycobacterium bovis, a bacterium closely related to Mycobacterium tuberculosis, the causative agent of tuberculosis (TB).

BCG vaccines stimulate the immune system to develop immunity against TB, reducing the risk of severe forms of the disease, such as meningitis and disseminated TB, in vaccinated individuals. BCG is also utilized as a form of immunotherapy in the treatment of non-muscle invasive bladder cancer. The BCG vaccines market is experiencing growth driven by the growing incidence of tuberculosis (TB) coupled with the rising awareness and adoption of vaccination programs.
 

TB remains a major global health issue, with millions of new cases reported every year. For instance, according to the World Health Organization, in 2022, there were 2.2 million new TB cases globally. Despite advancements in healthcare, TB continues to disproportionately affect low- and middle-income countries, where healthcare infrastructure may be insufficient to manage the disease effectively. The burden is further compounded by factors such as poverty, malnutrition, and HIV/AIDS, which weaken immune systems and increase susceptibility to TB infection.
 

Additionally, communities worldwide are becoming more health-conscious and informed about preventive healthcare measures. This heightened health literacy extends to understanding the importance of vaccination in preventing infectious diseases like TB. As people become more aware of the risks posed by TB and the effectiveness of BCG vaccination in mitigating those risks, the demand for BCG vaccines rises correspondingly.